← Back to headlines
Evolus Reaffirms 2026 Revenue and EBITDA Margin Targets
Evolus, a medical aesthetics company, has reiterated its net revenue guidance of $327 million to $337 million for 2026, alongside a target for a low to mid-single-digit adjusted EBITDA margin.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
